Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

NCT01433445 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Myelofibrosis
Post Essential Thrombocythemia Myelofibrosis
Post Polycythemia-Vera Myelofibrosis

Interventions

DRUG: panobinostat
DRUG: ruxolitinib

Sponsor

Novartis Pharmaceuticals